Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Case Report

Volume 1, Number 4, October 2011, pages 196-200

Rosuvastatin for Tocilizumab, an Interleukin-6 Receptor Antibody-induced Dyslipidemia in a Diabetic Patient Complicated With Rheumatoid Arthritis

Figures

Figure 1.
Figure 1. Effects of tocilizumab and rosuvastatin on serum interleukin (IL)-6 (A), high-sensitivity C-reactive protein (hs-CRP) (B) and adiponectin (C). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.
Figure 2.
Figure 2. Effects of tocilizumab and rosuvastatin on serum total cholesterol (TC) (A), triglyceride (TG) (B), low-density lipoprotein-cholesterol (LDL-C) (C) and high-density lipoprotein-cholesterol (HDL-C) (D). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.
Figure 3.
Figure 3. Effects of tocilizumab and rosuvastatin on serum low-density lipoprotein-cholesterol (LDL-C) (A), very low-density lipoprotein-cholesterol (VLDL-C) (B), intermediate-density lipoprotein-cholesterol (IDL-C) (C), chylomicron-cholesterol (CM-C) (D) and high-density lipoprotein-cholesterol (HDL-C) (E), determined by the high-performance liquid chromatography method. a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.
Figure 4.
Figure 4. Effects of tocilizumab and rosuvastatin on serum oxidized low-density lipoprotein (ox-LDL) (A) and small dense low-density lipoprotein (sd-LDL) (B). a, before the tocilizumab treatment; b, one month after the tocilizumab treatment and before the rosuvastatin use; c, two weeks after the rosuvastatin use.